Glancy Prongay & Murray LLP and Labaton Keller Sucharow LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of the Publicly Traded Common Stock of Athira Pharma, Inc. - (...
Athira Pharma, Inc. (ATHA)
Company Research
Source: PR Newswire
SEATTLE, June 10, 2024 /PRNewswire/ -- Nacif, et al. v. Athira Pharma, Inc., et al., Case No: 2:21-cv-00861-TSZ (W.D. Wash). SUMMARY NOTICE OF (I) PENDENCY OF CLASS ACTION AND PROPOSED SETTLEMENT; (II) FINAL APPROVAL HEARING;AND (III) MOTION FOR AN AWARD OF ATTORNEYS' FEESAND PAYMENT OF LITIGATION EXPENSESTO: All persons and entities who or which purchased or otherwise acquired Athira Pharma, Inc. ("Athira") publicly traded common stock during the period from September 17, 2020, through June 17, 2021, inclusive (the "Class Period"), and were damaged thereby (the "Class"):PLEASE READ THIS NOTICE CAREFULLY, YOUR RIGHTS WILL BE AFFECTED BY A CLASS ACTION SETTLEMENT YOU ARE HEREBY NOTIFIED, pursuant to Rule 23 of the Federal Rules of Civil Procedure, that the above-captioned litigation (the "Action") has been certified as a class action for settlement purposes, except for certain persons and entities who are excluded from the Class by definition as explained in the full printed Notice of
Show less
Read more
Impact Snapshot
Event Time:
ATHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATHA alerts
High impacting Athira Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
ATHA
News
- Athira Pharma, Inc. (NASDAQ: ATHA) was downgraded by analysts at Mizuho from an "outperform" rating to a "neutral" rating. They now have a $0.50 price target on the stock, down previously from $5.00.MarketBeat
- Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative DiseasesGlobeNewswire
- Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks [Yahoo! Finance]Yahoo! Finance
- Athira Pharma, Inc. (NASDAQ: ATHA) was downgraded by analysts at Rodman & Renshaw from a "buy" rating to a "neutral" rating.MarketBeat
- Athira Pharma, Inc. (NASDAQ: ATHA) was downgraded by analysts at BTIG Research from a "buy" rating to a "neutral" rating.MarketBeat
ATHA
Earnings
- 5/15/24 - Beat
ATHA
Sec Filings
- 9/17/24 - Form 8-K
- 9/5/24 - Form 144
- 9/5/24 - Form 4
- ATHA's page on the SEC website